Jiangsu Hengrui Pharma 
Welcome,         Profile    Billing    Logout  
 196 Products   52 Diseases   196 Products   3529 Trials   15381 News 


«12...678910111213141516...208209»
  • ||||||||||  MRTX1133 / BMS
    Unveiling mechanisms of MRTX1133 resistance in PDAC models (Section 19) -  Mar 17, 2026 - Abstract #AACR2026AACR_4906;    
    The established resistant models serve as physiologically relevant platforms for biomarker discovery and the development of rational combination therapies. Using these models, functional studies demonstrated that targeting core vulnerabilities
  • ||||||||||  trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma, AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
    SHR-A1811  (Hall H - Ground Level - Convention Center) -  Mar 17, 2026 - Abstract #AACR2026AACR_2482;    
    P1/2
    Background: Trastuzumab rezetecan (SHR-A1811) is a novel HER2-directed ADC approved for pretreated HER2-mutant NSCLC (Lancet Oncol, 2025). SHR-A1811
  • ||||||||||  Review, Journal:  JAK Inhibitors in the Treatment of T-Cell Lymphomas: Current Evidence and Future Directions. (Pubmed Central) -  Mar 14, 2026   
    Other drugs are currently being tested in clinicals trials, including pacritinib and ivarmacitinib, but results are not yet available...JAK inhibitors are associated with multiple adverse effects, including cytopenias and infections, and long-term safety data are lacking for newer agents. Future studies will need to clarify long-term safety and efficacy through well-designed clinical trials involving larger groups of patients.
  • ||||||||||  THE EFFICACY AND SAFETY OF PD-1 MONOCLONAL ANTIBODY IN THE TREATMENT OF HEMOPHAGOCYTIC SYNDROME:SYSTEMATIC REVIEW (VELAZQUEZ) -  Mar 14, 2026 - Abstract #EBMT2026EBMT_3711;    
    Future studies will need to clarify long-term safety and efficacy through well-designed clinical trials involving larger groups of patients. Data regarding the efficacy and safety of PD-1 monoclonal antibodies used (such as sintilimab, nivolumab, camrelizumab, and tislelizumab) in both pediatric and adult patients with HLH were included...In pediatric patients (aged 3
  • ||||||||||  Xiidra (lifitegrast) / Bausch Health, NovaTears (perfluorohexyloctane) / Novaliq, Bausch Health, AFT Pharma
    Enrollment open:  A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye Disease (clinicaltrials.gov) -  Mar 14, 2026   
    P2,  N=423, Recruiting, 
    Patients with GVHD or receiving immunosuppressants prior to therapy shows significantly lower MRD negativity rates. Not yet recruiting --> Recruiting
  • ||||||||||  HRS7415 / Jiangsu Hengrui Pharma
    Trial completion, Enrollment change, Trial completion date, Trial primary completion date:  A Study of HRS7415 Tablets in Patients With Advanced Malignant Tumors (clinicaltrials.gov) -  Mar 13, 2026   
    P1,  N=38, Completed, 
    Not yet recruiting --> Recruiting Not yet recruiting --> Completed | N=67 --> 38 | Trial completion date: Oct 2023 --> Mar 2025 | Trial primary completion date: Feb 2023 --> Mar 2025
  • ||||||||||  AiRuiKa (camrelizumab) / Elevar Therapeutics
    Intravesical versus intravenous therapy of Camrelizumab in BCG-unresponsive high-risk non (206) -  Mar 13, 2026 - Abstract #AUA2026AUA_3854;    
    No abstract available This first randomized exploratory study demonstrated a longer EFS and comparable safety profile using intravesical therapy of camrelizumab compared with intravenous therapy in patients with BCG-unresponsive HR-NMIBC.
  • ||||||||||  HR19042 / Jiangsu Hengrui Pharma
    Trial completion, Trial completion date:  A Study to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Primary IgA Nephropathy. (clinicaltrials.gov) -  Mar 12, 2026   
    P2,  N=316, Completed, 
    This first randomized exploratory study demonstrated a longer EFS and comparable safety profile using intravesical therapy of camrelizumab compared with intravenous therapy in patients with BCG-unresponsive HR-NMIBC. Trial completion date: Nov 2025 --> Aug 2025 | Active, not recruiting --> Completed
  • ||||||||||  AnDaJing (vunakizumab) / Jiangsu Hengrui Pharma
    Successful Treatment of Severe Generalized Pustular Psoriasis with Vunakizumab: A Case Report () -  Mar 12, 2026 - Abstract #AAD2026AAD_3968;    
    This case demonstrates that Vunakizumab can rapidly and effectively control both cutaneous and systemic manifestations of severe GPP. The favorable safety profile and significant clinical improvement support its potential as a therapeutic option for GPP.
  • ||||||||||  AnDaJing (vunakizumab) / Jiangsu Hengrui Pharma
    Vunakizumab Achieve Complete Remission of Severe Plaque Psoriasis in a 25-Year-Old Male with HIV Infection: A Case Report () -  Mar 12, 2026 - Abstract #AAD2026AAD_3433;    
    No treatment-related adverse events occurred during the treatment period, and the HIV infection did not worsen. Conclusion Vunakizumab led to PASI 100 in a patient with severe plaque psoriasis and HIV co-infection within eight weeks, while maintaining HIV stability and a favorable safety profile.As HIV-positive patients are often excluded from trials, real-world evidence like this case backs vunakizumab as a feasible, effective choice for this refractory group.
  • ||||||||||  Avida (trastuzumab rezetecan) / Jiangsu Hengrui Pharma
    Enrollment closed:  SHR-A1811-307: A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer (clinicaltrials.gov) -  Mar 11, 2026   
    P3,  N=868, Active, not recruiting, 
    Conclusion Vunakizumab led to PASI 100 in a patient with severe plaque psoriasis and HIV co-infection within eight weeks, while maintaining HIV stability and a favorable safety profile.As HIV-positive patients are often excluded from trials, real-world evidence like this case backs vunakizumab as a feasible, effective choice for this refractory group. Recruiting --> Active, not recruiting
  • ||||||||||  Hansoh Xinfu (flumatinib) / Jiangsu Hengrui Pharma, Jiangsu Hansoh Pharma
    Journal:  Non-receptor tyrosine kinase c-Abl downstream of C-type lectin receptors regulates innate antifungal immunity through c-Cbl/MAPK pathway. (Pubmed Central) -  Mar 11, 2026   
    Here, we report that inhibition of c-Abl with flumatinib mesylate significantly impairs the survival rate and exacerbates fungal burden in mice infected with Candida albicans...Collectively, our study uncovers a c-Abl/c-Cbl/MAPK signaling axis in dendritic cells that governs antifungal innate immunity, highlighting c-Cbl as a critical downstream mediator linking c-Abl to host defense against C. albicans. Our findings provide a mechanistic basis for fungal risk assessment in cancer patients treated with c-Abl inhibitors.
  • ||||||||||  AiTan (rivoceranib) / Elevar Therapeutics
    Journal:  Apatinib induces zebrafish hepatotoxicity by inhibiting Wnt signaling and accumulation of oxidative stress. (Pubmed Central) -  Mar 11, 2026   
    Apatinib induces down-regulation of key target genes of Wnt signaling pathway in zebrafish, and it is found that Wnt activator can significantly rescue liver developmental defects. These results suggest that apatinib may induce zebrafish hepatotoxicity by inhibiting the Wnt signaling pathway and up-regulating oxidative stress, helping to strengthen our understanding of rational clinical application of apatinib.